Searching in Pharma & Drug Safety · Search everything
2,610 changes Pharma & Drug Safety
Phase 1/2 mRNA Vaccine Glioblastoma Prevention Trial
ClinicalTrials.gov registered a Phase 1/2 clinical trial (NCT07520214) evaluating an mRNA vaccine for glioblastoma prevention. The trial will assess safety, tolerability, and immunogenicity of the investigational vaccine in participants at risk for glioblastoma. Healthcare providers and clinical investigators can reference this registration for study eligibility criteria and site locations.
Heart Failure Clinical Trial NCT07519892
The National Institutes of Health has registered clinical trial NCT07519892, a Heart Failure Clinical Trial, on the public ClinicalTrials.gov registry. The trial is listed with summary information accessible to the public. ClinicalTrials.gov is operated by the National Library of Medicine to promote transparency in clinical research.
Aducanumab Early Alzheimer's Disease Study
ClinicalTrials.gov registered a new Phase 3 clinical trial (NCT07519441) evaluating aducanumab for treatment of early Alzheimer's disease. The study will assess efficacy and safety in patients with early symptomatic Alzheimer's. Trial registration includes protocol details, eligibility criteria, and anticipated enrollment numbers.
NV-294 Microbiome Therapy Trial for Recurrent C. difficile Infection
The National Library of Medicine registered a new clinical trial (NCT07519686) on ClinicalTrials.gov evaluating NV-294, an investigational microbiome therapy, for treatment of recurrent Clostridioides difficile infection. The Phase 1/2 study will assess safety and efficacy in adult patients with recurrent C. difficile infection. Trial sponsors and clinical investigators must register applicable clinical trials on ClinicalTrials.gov per NIH requirements.
Apixaban-PK Trial for Portal Hypertension, Cirrhosis
ClinicalTrials.gov registered a new observational pharmacokinetic trial NCT07521332 evaluating apixaban in patients with portal hypertension and cirrhosis. The single-center study will collect PK data and assess clinical outcomes without administering study drug. Registration fulfills requirements under the FDA Amendments Act Section 801 for clinical trial disclosure.
Compositions and Methods for IV Administration of ABDNAZ for Cancer Treatment
USPTO published patent application US20260097013A1 for compositions and methods for intravenous administration of ABDNAZ (2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone) for cancer treatment. The application, filed on 2025-06-11, covers formulations containing autologous whole blood and ABDNAZ for rapid IV infusion. Inventors: Bryan T. Oronsky, Jan Scicinski, and Scott Caroen.
Field Safety Notices: 6 to 10 April 2026
MHRA published a weekly compilation of 15 Field Safety Notices (FSNs) for medical devices issued 6-10 April 2026. FSNs cover devices including gastric balloons, surgical systems, intraocular lenses, CT systems, and diagnostic equipment. MHRA notes it publishes FSNs for information only, and recipients must act on FSNs received directly from manufacturers.
Epoxytiglienone Compounds for Disrupting Gram-negative Bacterial Biofilms
The USPTO has published patent application US20260097011A1 for epoxytiglienone compounds designed to disrupt biofilms comprising Gram-negative bacteria. The application covers methods of dispersing established biofilms through localized administration, including topical or injection delivery, as well as methods for preventing biofilm formation on medical devices. Inventors include David William Thomas, Paul Warren Reddell, Glen Mathew Boyle, and others. The application was filed on December 2, 2025.
Compounds and Combinations Thereof for Treating Neurological and Psychiatric Conditions
The USPTO published patent application US20260097006A1 by inventor Herriot Tabuteau, filed September 4, 2025, covering compounds and combinations containing dextromethorphan for treating neurological and psychiatric conditions. The application discloses dosage forms and drug delivery systems typically combined with antidepressants such as bupropion. This publication makes the application publicly available for review and potential opposition.